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Introduction: Anaplastic lymphoma kinase (ALK) rearrangements 
occur in 1% to 7% of non–small-cell lung cancers (NSCLCs). 
Crizotinib, an ALK inhibitor, has been demonstrated to provide 
dramatic clinical benefits in ALK-positive advanced-stage NSCLC. 
Fluorescent in situ hybridization (FISH) has been established in 
clinical trials as the standard procedure method for detecting ALK 
rearrangements. Although the detection of ALK by immunohisto-
chemistry (IHC) has been proposed for the screening of patients, 
large-scale studies are warranted to validate such a hierarchical 
approach.
Methods: In this article, we report the largest series thus far of paral-
lel FISH and IHC ALK testing in 3244 consecutive NSCLC cases 
analyzed at two independent French centers.
Results: FISH-positive and/or IHC-positive results were demon-
strated in 150 of 3244 cases (4.6%). An imbalanced sex ratio was 
detected, with women exhibiting a 2.2-fold relative risk for an altera-
tion. Strikingly, only 80 of 150 specimens were classified as ALK 
positive by both techniques. The specimens with discordant FISH/
IHC analyses were FISH-positive/IHC-negative (36),  FISH-negative/
IHC-positive (19), or FISH-noncontributive/IHC-positive (15). Thus, 
a single FISH or IHC analysis performed alone would have failed 
to detect approximately one-fourth of the ALK-positive cases with 
similar findings in our two centers.
Conclusions: This study highlights the feasibility of systematic 
NSCLC testing by both FISH and IHC in routine practice. Many 
preanalytical factors may account for the apparent discrepancies 
between both methods, suggesting that hierarchical screening may 
underscore ALK-positive cases. This significant level of discrepancy 
supports the need of combined testing to optimize the detection of 
ALK-inhibitor–eligible patients given that some patients with discor-
dant testing were found to respond to crizotinib.
Key Words: Non–small-cell lung cancer, Anaplastic lymphoma 
kinase, Fluorescent in situ hybridization, Immunohistochemistry, 
Biomarker.
(J Thorac Oncol. 2014;9: 295–306)
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase encoded by a gene located on the chromosome arm 
2p. ALK was so named when it was discovered to be trans-
located [t(2;5)(p23;q35)] in anaplastic large-cell lymphoma, 
a subset of non-Hodgkin’s lymphoma. Recently, a fusion 
protein with transforming activity was described in non– -
small-cell lung cancer (NSCLC); this fusion was formed by 
a small inversion in the region of the chromosome 2 [Inv (2)
(p21;p23)] that joins the echinoderm microtubule–associated 
protein-like 4 (EML4) and ALK genes.1,2 The ALK chromo-
somal breakpoint commonly lies between exons 19 and 20 
but is variable on the EML4 side; more than 21 EML4-ALK 
variants have been identified.3 In addition to EML4, other 
translocation partners have been identified in NSCLC, nota-
bly kinesin family member 5B, TRK-fused gene, and kinesin 
light chain 1, leading to activation of signaling pathway and 
both experimental and clinical responses to ALK inhibitors.4 
Crizotinib is a potent and selective ATP-competitive inhibitor 
of the MNNG HOS transforming gene (MET) and ALK tyro-
sine kinases which has been patented by Pfizer. In the phase 
I/II trials enrolling NSCLC patients with documented ALK 
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rearrangements, the objective response rates were impres-
sive (60%). Most responses were achieved during the first 
8 to 9 weeks of treatment, and the duration of the response 
was approximately 45 to 50 weeks.5 Consequently, crizotinib 
(Xalkori, Pfizer) obtained by an accelerated Food and Drug 
Administration approval in 2011 and, more recently, the mar-
keting authorization of the European Medicines Agency. In 
addition, recent data from phase I/II trials with second-gen-
eration ALK tyrosine kinase inhibitors (LDK378, AP26113) 
revealed promising response rates in patients who had 
relapsed from crizotinib.6,7 These results highlight the ethical 
need to perform exhaustive and efficient screening of NSCLC 
patients to diagnose the patients who are most likely to benefit 
from this new therapy. According to the majority of the series, 
the ALK locus rearrangement was observed in 1% to 7% of 
NSCLCs, without Kirsten rat sarcoma (KRAS)- or epider-
mal growth factor receptor (EGFR)-associated mutations.8–12 
Moreover, ALK-rearranged NSCLCs are thought to exhibit 
unique clinicopathological features, such as young age, a 
negative or light history of smoking, advanced clinical stage, 
and solid histology with signet ring cells.13–15 The selection of 
patients on the basis of adenocarcinoma histology, the absence 
of EGFR/KRAS and ERBB2 mutation, less than a 20 pack/year 
history of smoking, and poor or moderate cell differentiation 
has been shown to increase the rate of detection up to 29.6% 
and has been proposed as an algorithm to select patients for 
testing.16 However, other studies demonstrated that selecting 
patients on a clinical and morphological basis is not sufficient 
to identify NSCLC patients with ALK rearrangements.14,17
Currently, the only approved companion test for the 
detection of ALK positivity is fluorescent in situ hybridiza-
tion (FISH) using break-apart (BA) probes (Food and Drug 
Administration new drug application: 202570). Such test-
ing has been validated in clinical trials to select patients 
who respond to crizotinib. For some authors, FISH may not 
be suitable for large-scale screening because of its running 
costs, the need for trained observers, and adapted equipment. 
 Reverse-transcription polymerase chain reaction (RT-PCR) or 
immunohistochemistry (IHC) are thought to represent alterna-
tive methods. However, the large number of currently known 
and not yet unraveled ALK translocation partners makes the 
identification of all variants by molecular techniques such as 
RT-PCR prohibitively difficult.18 With respect to IHC, new 
antibodies for the detection of the chimeric ALK protein have 
been validated along with FISH and RT-PCR.14,17,19–23 IHC was 
found to be a reliable screening tool, but standardization of its 
interpretation has not yet been established.24
In this article, we have compiled the unselected data of 
two independent groups who performed daily parallel analy-
ses of ALK rearrangements by FISH and ALK protein detec-
tion by IHC. This study documents a large-scale testing of 
ALK in 3244 unselected NSCLC patients. Concordance of 
the data obtained by the two groups highlights the feasibil-
ity of ALK FISH testing in routine practice using automated 
systems and reveals a significant level of discrepancy between 
the FISH and IHC results.
MATERIALS AND METHODS
Ethics Statement
This study was approved by the institutional ethics 
committees of the Rennes and Bordeaux university hospitals, 
which waived the need for informed consent because of the 
observational nature of the study. The study was performed 
using routine FISH and IHC testing. Collection of the data and 
further analyses, such as statistical testing, were performed 
anonymously.
Patient Cohort
A total of 3244 NSCLC patients were consecutively 
referred to the Rennes and Bordeaux pathology and cytogenet-
ics departments for the evaluation of ALK status. In Rennes, 
the cohort consisted of 1843 cases of NSCLCs, including 
1289 male and 554 female patients. This cohort was histologi-
cally classified as 1393 adenocarcinoma, 294 squamous cell 
carcinoma (SCC), eight adenosquamous cell carcinoma, and 
148 not otherwise specified (NOS) cases. In Bordeaux, the 
recruitment focused on samples with adenocarcinoma histol-
ogy. Nine patients with SCC were also studied because they 
occurred in young patients or in light smokers. The cohort 
consisted of 1401 patients (842 male and 559 female patients) 
with tumors histologically classified as 1203 adenocarcinoma, 
nine SCC, six adenosquamous cell carcinoma, and 183 NOS 
(Tables 1 and 2). The histological classification was on the 
basis of hematoxylin-eosin staining and phenotypical markers 
(thyroid transcription factor-1, P63, and cytokeratins 5/6/7).
Fluorescent In Situ Hybridization
Specimens for biopsy originating from different periph-
eral sites were extemporaneously prepared in the central molec-
ular analysis platform and analyzed within 1 week. Interphase 
FISH analysis was performed on 4-μm sections of formalin- or 
alcohol–formol–acetic-acid–fixed,  paraffin-embedded tumor 
TABLE 1.  Characteristics of the Patients
Total Cases ALK-Positive Cases
Number 3244 150
Age 65 ± 11 (24–95) 63 ± 13 (28–95)
Sex
  Male 2131 69
  Female 1113 81
Histology
  ADK 2596 131
  SSC 303 3
  ADSK 14 2
  NOS 331 14
Mutations
  EGFR 311 8
  KRAS 681 14
Age: mean ± SD (min–max).
ADK, adenocarcinoma; ADSK, adenosquamous cell carcinoma, SCC, squamous 
cell carcinoma; NOS, not otherwise specified; ALK, anaplastic lymphoma kinase; EGFR, 
epidermal growth factor receptor; KRAS, Kirsten rat sarcoma.
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TABLE 2.  Characteristics of the Patients with ALK Alterations
Patient
ALK 
FISH
FISH  
Pattern
Positive  
Nuclei 
(%)
Score 
IHC
Age 
(yr) Sex Histology
Tumor 
Site
Surgical 
Procedure
Tumor  
Cell 
(%)
EGFR/KRAS  
Mutation Therapy
Crizotinib  
Response
Rennes University Hospital
1 POS IRS 76 2/3+ 72 F ADK P OS >50 No Chemo
2 POS IRS 54 2/3+ 69 M ADK P B 25–50 No Crizo Yes
3 POS BA 16 2/3+ 66 M ADK P B >50 No Surg
4 POS IRS 30 2/3+ 54 M ADK P B 10–25 No Crizo Yesa
5 POS BA 27 2/3+ 74 F ADK P B >50 No Crizo Yes
6 POS BA 17 2/3+ 49 M ADSK P B 10–25 No Crizo Yesa
7 POS BA 24 2/3+ 49 F ADK M L >50 No Crizo Yes
8 POS BA 16 2/3+ 60 F ADK P B 10–25 No Chemo
9 POS IRS 26 2/3+ 87 M ADK P B >50 No Died
10 POS BA 45 2/3+ 49 F ADK M B 25–50 No Crizo Yes
11 POS BA 25 2/3+ 64 F ADK P B 25–50 No Surg
12 POS BA 50 2/3+ 63 F ADK M OS >50 No Crizo Yes
13 POS BA 55 2/3+ 67 F ADK P TP >50 No Crizo Yes
14 POS BA 50 2/3+ 58 F ADK P B >50 No Crizo Yes
15 POS BA 60 2/3+ 70 F ADK P B >50 No Chemo
16 POS BA 20 2/3+ 59 F ADK P B >50 No Chemo
17 POS BA 65 2/3+ 35 F ADK M OS >50 No Crizo Yes
18 POS BA 40 2/3+ 60 F ADK M OS >50 No Crizo Yes
19 POS BA 65 2/3+ 79 M ADK M B 10–25 No Died
20 POS BA 57 2/3+ 77 F ADK M B >50 No Crizo Yes
21 POS BA 18 2/3+ 78 F ADK M L 10–25 No Crizo Yes
22 POS BA 60 2/3+ 78 F ADK P B >50 No Crizo Yes
23 POS IRS 50 2/3+ 74 F ADK M B >50 ND Died
24 POS BA 50 2/3+ 76 M ADK P OS 25–50 No Crizo Yes
25 POS IRS 30 2/3+ 76 F ADK M L 25–50 No Chemo
26 POS BA 55 2/3+ 67 F ADK P OS >50 No Chemo
27 POS IRS 60 2/3+ 78 M ADK P B >50 No Crizo Yes
28 POS IRS 80 2/3+ 74 F ADK P B >50 No Chemo
29 POS BA 50 2/3+ 49 M ADK P B 10–25 No Chemo
30 POS BA 55 2/3+ 31 F ADK P OS 25–50 No Chemo
31 POS BA 40 2/3+ 41 M ADK P B >50 No Crizo Yes
32 POS IRS 70 2/3+ 65 M ADK ND B 25–50 No Radioth
33 POS BA 80 1+ 93 F NOS M L >50 No Died
34 POS BA 40 0 73 F ADK P OS >50 No Surg
35 POS BA 18 0 58 M ADK M B >50 No Died
36 POS BA 50 0 60 M ADK P B >50 No None
37 POS BA 20 0 72 F NOS P B 10–25 No Died
38 POS BA 18 0 55 M ADK M OS >50 No Chemo
39 POS BA 63 0 61 M ADK P B >50 No Chemo
40 POS IRS 60 0 72 M SCC P B 25–50 No Chemo
41 POS IRS 60 0 65 M ADK P OS >50 L858R + T790M Crizo Yes
42 POS IRS 60 0 63 F ADK M B >50 No Crizo Yes
43 POS IRS 60 0 80 F NOS P B >50 No None
44 POS IRS 30 0 58 M ADK P B >50 KRAS Chemo
45 POS IRS 45 0 67 M ADK P OS >50 KRAS Chemo
46 POS BA 60 0 66 M ADK M B >50 No Crizo Yes
47 NEG / / 2/3+ 45 F ADK M OS >50 No Crizo Yes
48c NEG / / 2/3+ 66 F ADK P OS >50 No Chemo
(Continued)
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49 NEG / / 2/3+ 62 M ADK M L >50 KRAS Chemo
50 NEG / / 2/3+ 67 F ADK M B >50 No Chemo
51 NC / / 2/3+ 52 F ADK M B 25–50 NC Crizo Yes
52 NC / / 2/3+ 95 F ADK M L 25–50 No None
53 NC / / 2/3+ 65 F ADK P B 10–25 No Crizo Yesb
54 NC / / 2/3+ 82 F ADK P B 25–50 No Lost
55 NC / / 2/3+ 61 M ADK P B 25–50 NC Chemo
56 NC / / 2/3+ 68 F ADK P OS >50 NC Surg
57 NC / / 2/3+ 45 M ADK P B <10 NC Chemo
58 NC / / 2/3+ 77 F ADK M B <10 Del19 Died
59 NEG / / 1+ 52 M ADK P OS 25–50 Del19 Surg
60 NEG / / 1+ 51 M ADK P B >50 No Surg
61 NEG / / 1+ 65 F ADK P TP 25–50 Del19 Surg
62 NEG / / 1+ 65 M ADK P OS 25–50 L858R Gefitinib
63 NEG / / 1+ 63 F ADK M OS >50 No Chemo
64 NEG / / 1+ 69 M ADK P B 25–50 KRAS Died
65 NEG / / 1+ 70 F ADK P OS >50 KRAS Chemo
66 NC / / 1+ 56 M ADK P B 25–50 KRAS Chemo
67 NC / / 1+ 77 M ADK P B >50 No Died
68 NC / / 1+ 80 F ADK P B >50 NC Chemo
Bordeaux University Hospital
69 POS BA 15 2/3+ 67 F ADK P B >50 No Crizo Yesa
70 POS BA 20 2/3+ 80 F ADK P OS >50 No Chemo
71 POS BA 20 2/3+ 64 F ADK M OS >50 No Lost
72 POS IRS 80 2/3+ 62 F ADK P OS >50 No Crizo Yes
73 POS IRS 15 2/3+ 52 M ADK P B 25–50 No Crizo Yesa
74 POS BA 35 2/3+ 82 M ADK P L >50 No Chemo
75 POS IRS 30 2/3+ 38 M ADK P B 10–25 No Crizo Yes
76 POS IRS 40 2/3+ 56 F ADK P OS >50 No Chemo
77 POS BA 60 2/3+ 68 M ADK P B >50 No Died
78 POS BA 40 2/3+ 35 F ADK P OS >50 No Crizo Yesa
79 POS BA 60 2/3+ 58 F ADK P OS >50 No Lost
80 POS BA 55 2/3+ 80 M ADK M B 10–25 NC/No Lost
81 POS IRS 30 2/3+ 44 F ADK P B >50 No Radioth
82 POS BA 16 2/3+ 28 M NOS P B >50 No Crizo Yesa
83 POS IRS 50 2/3+ 41 F ADK P OS 25–50 No/NC Lost
84 POS IRS 90 2/3+ 65 F ADK P OS >50 No Lost
85 POS IRS 50 2/3+ 70 F ADK M OS >50 ND Crizo Yes
86 POS BA 60 2/3+ 28 M ADK P B 10–25 ND Crizo Yes
87 POS IRS 60 2/3+ 67 F ADK M OS 25–50 No Radioth
88 POS IRS 50 2/3+ 84 F ADK P B 10–25 No Chemo
89 POS IRS 70 2/3+ 72 F ADK P B 25–50 No Crizo Yes
90 POS IRS 50 2/3+ 78 M ADK P OS 25–50 No Crizo Yes
91 POS BA 80 2/3+ 41 M ADK P OS >50 No Crizo Yes
92 POS BA 40 2/3+ 71 M ADK P B 25–50 No Chemo
93 POS BA 90 2/3+ 58 F ADK P OS >50 No Lost
94 POS IRS 90 2/3+ 57 F ADK P OS >50 No Surg
95 POS BA 40 2/3+ 40 M ADK P OS >50 No Crizo Unknown
96 POS BA 90 2/3+ 67 M ADK P B 25–50 ND Lost
TABLE 2. (Continued)
Patient
ALK 
FISH
FISH  
Pattern
Positive  
Nuclei 
(%)
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IHC
Age 
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Surgical 
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TABLE 2. (Continued)
Patient
ALK 
FISH
FISH  
Pattern
Positive  
Nuclei 
(%)
Score 
IHC
Age 
(yr) Sex Histology
Tumor 
Site
Surgical 
Procedure
Tumor  
Cell 
(%)
EGFR/KRAS 
Mutation Therapy
Crizotinib  
Response
97 POS BA 35 2/3+ 72 M ADK M B >50 No Crizo Not evaluated
98 POS BA 30 2/3+ 86 M ADK P B >50 No Crizo Stabilization
99 POS BA 20 2/3+ 48 M ADK M B ND No Surg
100 POS BA 40 2/3+ 59 M ADK P B >50 No Lost
101 POS IRS 40 2/3+ 51 F NOS P B >50 No Died
102 POS BA 20 2/3+ 65 M NOS P B 25–50 No Erlotinib
103 POS BA 80 2/3+ 51 F ADK P B 25–50 No Chemo
104 POS BA 60 2/3+ 79 F ADSK P B 25–50 No Crizo Yesb
105 POS BA 60 2/3+ 55 M ADK M OS >50 No Chemo
106 POS BA 30 2/3+ 51 M ADK P L 25–50 No Died
107 POS BA 50 2/3+ 39 M NOS M B 25–50 No Lost
108 POS BA 50 2/3+ 54 M ADK M B >50 No Lost
109 POS BA 50 2/3+ 70 F ADK M B >50 No Chemo
110 POS IRS 65 2/3+ 56 F ADK P B >50 No Crizo Yes
111 POS IRS 50 2/3+ 66 F ADK P OS 10–25 No Lost
112 POS BA 15 2/3+ 59 F ADK ND B 25–50 No Chemo
113 POS BA 40 2/3+ 44 M ADK M B >50 No Lost
114 POS BA 50 1+ 82 F ADK M B >50 No Crizo Yes
115 POS BA 15 1+ 82 F ADK P B 25–50 No Died
116 POS BA 15 0 70 M ADK P B >50 KRAS Chemo
117 POS BA 15 0 65 F ADK P OS >50 KRAS Chemo
118 POS IRS 70 0 69 M ADK P OS >50 No Surg
119 POS IRS 70 0 56 M NOS P OS >50 No Surg
120 POS BA 15 0 61 F ADK M OS >50 KRAS Chemo
121 POS BA 60 0 53 M ADK P B 25–50 No Lost
122 POS IRS 20 0 62 M ADK P B 25–50 L858R Gefitinib
123 POS IRS 15 0 63 F ADK M OS >50 KRAS Radioth
124 POS IRS 40 0 72 M ADK P OS >50 No Surg
125 POS BA 20 0 64 M ADK P OS 10–25 KRAS Crizo Stabilizationa
126 POS IRS 15 0 46 F ADK M B 25–50 No Died
127 POS BA 15 0 52 F ADK P OS >50 No Surg
128 POS BA 15 0 73 F NOS P B >50 L858R Gefitinib
129 POS BA 15 0 63 M ADK P OS >50 No Crizo Yes
130 POS BA 15 0 59 M NOS M B >50 No Chemo
131 POS BA 25 0 46 F ADK P B 25–50 No Died
132 POS BA 15 0 71 M SCC P B >50 No Crizo No
133 POS BA 15 0 83 M ADK P B 10–25 No Chemo
134 POS BA 30 0 40 F NOS P OS >50 No Surg
135 POS IRS 15 0 42 M ADK M B >50 No Died
136 POS BA 20 0 66 F NOS P B >50 No Chemo
137 POS IRS 15 0 50 F ADK P TP >50 KRAS Erlotinib
138 POS BA 20 0 54 M ADK M B >50 No Not yet treated
139 NEG / / 2/3+ 48 M NOS P B 25–50 No Chemo
140 NEG / / 2/3+ 67 F ADK P OS >50 No Chemo
141 NEG / / 2/3+ 76 M SCC M OS >50 No Chemo
142 NEG / / 2/3+ 68 M ADK P OS >50 L858R Surg
143 NEG / / 2/3+ 77 M ADK M B >50 No Chemo
144 NEG / / 2/3+ 60 F NOS P B 25–50 KRAS Died
145 NEG / / 2/3+ 63 F ADK M OS >50 No Chemo
(Continued)
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tissues. The Abbott BA probe (Vysis ALK Dual-Color; Abbott, 
Rungis, France) and the Dako split probe (Dako, Glostrup, 
Denmark) were assessed in the Rennes and Bordeaux cohorts, 
respectively. Both Vysis and Dako probes had been previously 
validated to provide equivalent results with the use of 100 
NSCLC samples (our unpublished results).
Because tumor cells could be unequally distrib-
uted within the sample (focal infiltrations), an adjacent 
 hematoxylin-eosin–stained section was used to delimit the 
area of interest and to determine the percentage of tumor 
cells. The protocols differ slightly between the two centers. 
In Rennes, the slides were deparaffinized with xylene using 
a VP2000 processor (Abbott, Wiesbaden, Germany). The 
tissue was then digested with pepsin (Dako) for 8 minutes. 
The target DNA and probe were codenatured for 3 minutes 
at 73°C by using a programmable system (Thermobrite; 
Abbott), and probe hybridization was performed overnight 
in a humidified atmosphere at 37°C. In Bordeaux, FISH 
analysis was conducted with the histology FISH accessory 
kit (Dako). Slides were deparaffinized with toluene. The tis-
sue was then digested with pepsin (Sigma-Aldrich, St. Louis, 
MO) for 10 minutes. The target DNA and probe were codena-
tured for 5 minutes at 82°C by using a programmable system 
(Dako), and probe hybridization was performed overnight in 
a humidified atmosphere at 45°C.
Slides were analyzed with a fluorescence microscope 
(Axioskop2, Axio Imager Z2 or Axioplan [Zeiss, Göttingen, 
Germany]; BX61 [Olympus, Rungis, France]) and Isis imag-
ing software (Metasystems, Altlussheim, Germany). The entire 
hybridized surface was screened using a double  band-pass filter 
with an ×63 objective to detect areas with abnormal patterns 
and to focus the scoring. FISH scoring was performed under 
both real-time conditions at the microscope and with the use of 
z-stack images. Specific recommendations for ALK-rearranged 
pattern determination were used.25,26 At least 100 nonoverlap-
ping tumor nuclei were examined. Nuclei were not scored if 
the signals were weak, diffuse, of only one color, or in areas 
with stretching of the signal and nuclei. The pattern was consid-
ered positive for cells exhibiting BA (signals separated by a gap 
larger than two diameters) or isolated red signals (IRSs, deletion 
of the 5' ALK region). Scoring was performed in areas or clus-
ters with the most abnormal pattern and not as a mean of ran-
domly selected tumor areas. FISH for ALK locus rearrangement 
was considered positive if 15% or more nuclei were positive. 
Cases with high levels of polysomy, defined by the presence 
of greater than six fusion signals in more than 15% of tumor 
cells, were also registered. After establishing the case report by 
two independent observers, we also took into consideration the 
immunohistochemical results. All FISH slides with borderline 
positivity (15%) or discordant data between FISH and IHC 
were then reviewed by two additional experienced observers 
without the knowledge of which pattern had been reported and 
the IHC data. A final consensus decision was then determined 
on the basis of the scoring of at least three observers.
Immunohistochemistry
IHC was assayed in both centers on 4-μm formalin- 
or alcohol–formol–acetic-acid–fixed, paraffin-embedded 
tumor tissues by using a primary monoclonal ALK anti-
body (mAb) from Abcam (clone 5A4; Abcam, Cambridge, 
United Kingdom). In Rennes, IHC analysis was performed 
using a Ventana automated immunostainer (Ventana Medical 
Systems, Illkirch Graffenstaden, France); the slides were dried 
at 60°C for 1 hour, deparaffinized using EZ Prep at 75°C for 
4 minutes, and incubated with the primary mAb at a dilution 
of 1:50 for 1 hour at 37°C. Detection was performed using 
a multimer-technology system with the UltraView Universal 
DAB detection kit with which the pathologists have a vast 
experience. Note that Ventana markets another detection 
kit, the OptiView system, which was not used in Rennes. In 
Bordeaux, IHC assays were performed by using a Bond-maX 
automated immunostainer (Leica Microsystems, Inc., Buffalo 
Grove, IL); the slides were dried at 60°C for 30 minutes, depa-
raffinized using Bond Dewax Solution (Leica Microsystems) 
at 72°C for 3 minutes, and incubated with the primary mAb 
at a dilution of 1:50 for 15 minutes at room temperature. 
Detection was performed using the Bond Polymer Refine 
Detection system (Leica Microsystems).
146 NEG / / 1+ 68 F ADK P B >50 No Crizo Yes
147 NC / / 2/3+ 65 M ADK P L >50 No Chemo
148 NC / / 2/3+ 70 F ADK P B 10–25 No Crizo Toxicity
149 NC / / 2/3+ 61 F ADK P B 25–50 No Crizo Yesb
150 NC / / 1+ 66 F ADK P L 25–50 KRAS Surg
aRelapse after initial response.
bTreatment was stopped because of toxicity.
cOf note, a sample from a distant metastatic site has been analyzed blindly several months later and revealed same discrepancy. FISH/IHC discordant results are highlighted in grey.
BA, break-apart profile; IRS, isolated red signal profile; M, male; F, female; ADK, adenocarcinoma; ADSK, adenosquamous cell carcinoma; SCC, squamous cell carcinoma; NOS, 
not otherwise specified; P, primitive tumor; M, metastasis; OS, operative specimen; B, biopsy; TP, transparietal punction; L, liquid; NC, unsuccessful analyse; ND, undetermined or 
missing data; L858R, arginine for leucine substitution at amino acid 858 in EGFR; T790M, methionine for threonine substitution at amino acid 790 in EGFR; del19, exon 19 deletion 
in EGFR; Surg, patient treated only by surgery; chemo, chemotherapy; radioth, radiotherapy; crizo, crizotinib; died, patient died soon after being diagnosed before a treatment could 
be started; lost, lost to follow-up; ALK, anaplastic lymphoma kinase; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; EGFR, epidermal growth factor receptor; 
KRAS, Kirsten rat sarcoma; POS, positive; NEG, negative.
TABLE 2. (Continued)
Patient
ALK 
FISH
FISH  
Pattern
Positive  
Nuclei 
(%)
Score 
IHC
Age 
(yr) Sex Histology
Tumor 
Site
Surgical 
Procedure
Tumor  
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(%)
EGFR/KRAS 
Mutation Therapy
Crizotinib  
Response
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A positive external control consisting of a slide of a 
previously FISH-validated ALK-rearranged and IHC-positive 
sample was included in all tests. Semi-quantitative assessment 
was performed by one observer (HB, LD, or DC) by estimating 
the staining intensity and percentage of tumor cells with posi-
tive cytoplasmic staining. Samples were then placed into four 
categories with negative, faint, and/or doubtful heterogeneous 
staining (1+) and moderate to intense homogeneous staining 
(2 to 3+); noncontributive IHC results were also recorded when 
the number of tumor cells was to found to be too low because 
of sample exhaustion or artifacts (necrosis, etc.).
Statistical Analysis
The Mann–Whitney rank-sum test and χ2 test were per-
formed with Sigma-Stat software (Systat Software, San Jose, 
CA). A p value of 0.05 was considered statistically significant.
RESULTS
Characteristics of ALK-Positive Patients 
Evidenced Either by FISH or by IHC
A total of 150 patients (4.6%) were found to be ALK 
positive by FISH and/or IHC (Tables 1 and 2). Among those 
identified as positive, 68 patients (3.7%) were in Rennes and 
82 patients (5.8%) were in Bordeaux. The mean age of the 
ALK-positive patients was not significantly different from that 
of the entire cohort (p = 0.055; Table 1). The data revealed an 
imbalanced sex ratio (p < 0.0001; Table 1), with a relative risk 
of 2.2-fold for female patients to exhibit an ALK alteration. 
Female patients represented 57% (39 of 68) and 51% (42 of 82) 
of the ALK-positive patients, whereas they accounted for 30% 
(554 of 1843) and 40% (559 of 1401) of the patients in Rennes 
and Bordeaux, respectively. The vast majority of the tumors 
screened in the study were adenocarcinomas, for which the rate 
of ALK positivity reached 5% (Tables 1 and 2). Of note, the 
rate of detection of ALK positivity for NOS NSCLC was 4.2% 
(14 of 331). By contrast, only three of 303 SCCs (1%) were 
classified as positive. This may partly account for the lower 
detection rate in the Rennes cohort, where 294 SCC cases were 
included, in contrast to the Bordeaux cohort. Moreover, among 
the ALK-positive cases, 22 of 150 cases were found in associa-
tion with KRAS (14) or EGFR (8) mutations (Tables 1 and 2).
FISH Analysis
FISH analysis identified 116 ALK gene rearrangements, 
accounting for 3.6% of the patients (Table 2). The percentages 
of FISH-positive cases were 2.5 and 5 in Rennes and Bordeaux, 
respectively. Illustrations of positive BA and IRS patterns are 
depicted in Figure 1, as are samples with polysomy. The per-
centage of positive nuclei exhibiting either a BA or IRS pattern 
was highly variable (Fig. 2). The positive cases more frequently 
exhibited the BA pattern (66%). Moreover, the BA pattern was 
characterized by a lower percentage of positive nuclei com-
pared with that observed in the IRS pattern (p = 0.021) (Fig. 2).
IHC Analysis
IHC analysis identified 114 ALK-positive samples 
(3.5%) (Tables 1 and 2). Overexpression of ALK protein 
Negative: FusionPositive: 2/3+x400
FISHIHCHE
Negative: polysomyPositive: 2/3+
Negative: polysomyPositive: 1+
Positive: IRS patternNegativex400
Positive: BA patternNegativex200
x200
x200
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I
J
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FIGURE 1.  Illustration of discordant cases of ALK gene 
rearrangement and ALK protein overexpression. HE staining 
(A–E), IHC staining (F–J), and FISH patterns (K–O) of 4-μm–
fixed, paraffin-embedded tissue sections of non–small-cell 
lung cancer. FISH analysis was performed with separating 
probes flanking the breakpoint of the ALK gene. IHC analy-
sis was performed with an anti-ALK mouse monoclonal 
antibody (clone 5A4; Abcam). A, F, and K, A case exhibiting 
positive (2/3+) IHC staining (F) and a negative FISH result 
with adjacent orange/green or yellow fusion signals (K). B, 
G, and L, A case exhibiting negative IHC staining (G) and a 
rearranged-ALK gene with a BA pattern (L). C, H, and M, A 
case exhibiting negative IHC staining (H) and a rearranged-
ALK gene with an IRS pattern (M). D, I, and N, A case exhib-
iting heterogeneity of ALK immunostaining with either low 
(1+) staining of most tumor cells or moderate staining (2+) 
of large polylobulated cells (I) and high polysomy with the 
presence of greater than six fusion signals (N). E, J, and 
O, A case exhibiting positive (2/3+) IHC staining (J) and 
high polysomy with the presence of greater than six fusion 
signals (O). IHC, immunohistochemistry; HE, hematoxylin-
eosin; FISH, fluorescent in situ hybridization; BA, break-
apart; IRS, isolated red signal; ALK, anaplastic lymphoma 
kinase.
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was detected in 3% and 4.2% of the cases in Rennes and 
Bordeaux, respectively. Moderate to intense homogeneous 
staining (score 2/3+) was observed in 99 cases although 15 
samples were considered to exhibit faint and/or doubtful het-
erogeneous staining (score 1+). Illustrations of negative, faint/
doubtful, and intense staining are presented in Figure 1.
Comparison between FISH and IHC Analyses
When compiling the results, a 4.6% (150 of 3244) rate of 
detection of ALK positivity was achieved using parallel com-
bined FISH and IHC testing. Only 53% (80 of 150) of the sam-
ples classified as positive were in fact identified by both FISH 
and IHC analyses (Fig. 3A). Without considering the noncontrib-
utive FISH cases, the two analytic methods led to 55 discordant 
results (24 in Rennes and 31 in Bordeaux). In the FISH-positive/
IHC-positive cases, IHC staining was mostly intense: 77 sam-
ples were scored 2/3+, whereas only three cases exhibited faint 
staining, suggesting an apparent correlation between both tech-
niques for intensely stained IHC cases (Fig. 3B). However, there 
was no correlation between the percentage of tumor cells with 
ALK rearrangements and the intensity of IHC staining (Table 2).
In Rennes, 68 samples (3.7%) were diagnosed as ALK 
positive, but only 33 patients (1.8%) were positive for both ALK 
gene rearrangement and ALK protein overexpression (Table 2). 
FISH evidenced 13 ALK rearrangements without protein immu-
nodetection. FISH-positive/IHC-negative cases accounted for 
28% (13 of 46) of the patients diagnosed by FISH analysis 
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FIGURE 2.  Percentage of positive nuclei in non–small-cell 
lung cancer harboring ALK rearrangements. Box-and-whisker 
plot of the percentage of positive nuclei in the FISH-positive 
samples. ALK locus rearrangement was considered positive 
if 15% or more nuclei exhibited BA or IRS patterns. The 
distribution is shown for all FISH-positive cases (n = 116), 
BA-positive cases (n = 77), and IRS-positive cases (n = 39). 
The line in the box represents the median, and the borders 
of the box represent the lower and upper quartiles of the 
data, respectively. The ends of the whiskers represent the 
minimum and maximum of all data. The threshold of 15% 
is depicted on the graph. FISH, fluorescent in situ hybridiza-
tion; IRS, isolated red signal; BA, break-apart; ALK, anaplastic 
lymphoma kinase.
FIGURE 3.  Comparative FISH and IHC analyses. A, 
Histograms of the repartition of the IHC results (positive or 
negative) in the 116 FISH-positive cases and the repartition 
of the FISH results (positive, negative, and noncontributive) 
in the 114 IHC-positive cases. B, Histograms of the reparti-
tion of the IHC score (0, 1+, 2/3+) in the 116 FISH-positive 
cases. C, Histograms of the IHC results in the 116 FISH-
positive cases. Rennes: 46 FISH-positive cases; Bordeaux: 70 
 FISH-positive cases. The values on the bars are the percentage 
of  IHC-positive and IHC-negative results. FISH, fluorescent in 
situ hybridization; IHC, immunohistochemistry.
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(Fig. 3C). These 13 patients did not harbor a specific ALK rear-
rangement pattern (7 BA and 6 IRS) (Table 2). Furthermore, 11 
 IHC-positive samples (4 samples with a 2/3+ score and 7 with a 
1+ score) were classified as negative by FISH.
In Bordeaux, 82 samples (5.9%) exhibited either 
ALK gene rearrangements or ALK overexpression. Only 47 
patients (1.4%) were positive by both techniques (Table 2). 
FISH revealed ALK rearrangements in 23 IHC-negative cases. 
Consistent with the results in Rennes, the  FISH-positive/IHC-
negative cases represented 33% (23 of 70) of the cases iden-
tified by FISH (Fig. 3C). In such cases, ALK rearrangement 
patterns were BA in 15 and IRS in eight cases, which did not 
differ from patients with a combined FISH/IHC positivity (31 
and 16, respectively). In addition, eight IHC-positive samples 
(7 scored 2/3+ and 1 scored 1+) were FISH negative (Table 2). 
Three of these eight discordant  FISH-negative/IHC-positive 
cases were also analyzed by using the Abbott ALK BA probes, 
which revealed similar FISH-negative results (data not shown). 
Furthermore, four cases were IHC positive, whereas the FISH 
analysis was not contributive because of hybridization failure 
or an insufficient number of tumor cells.
The performance of each test, if theoretically performed 
sequentially, was compared in the entire cohort. First, FISH 
analysis performed would have detected the ALK rearrange-
ments in 116 of the 3244 patients (3.6%) although IHC analy-
sis would have detected ALK expression in an additional set 
of 34 patients that were negative (n = 19) or noncontributive 
(n = 15) by FISH (Table 3). Conversely, if IHC had been the 
first technique used, 114 positive cases (3.5%) would have 
been detected, and FISH testing would have revealed ALK 
positivity in an additional set of 36 patients (Fig. 3A and Table 
3). Preliminary data from 44 evaluable patients demonstrate a 
high response rate in the crizotinib-treated population. Most 
interestingly, some responses were also observed in both dis-
cordant FISH+/IHC− and FISH−/IHC+ patients (Table 2).
DISCUSSION
The discovery of ALK rearrangements in a subset of 
NSCLC2 has rapidly led to the validation of the ALK inhibitor 
crizotinib in a phase III trial in which patients were enrolled 
on the basis of a positive BA FISH assay.18 For the detec-
tion of ALK-positive cases, BA or IRS patterns and a posi-
tive threshold of 15% with scoring at a minimum of 60 nuclei 
were defined.25,26 The evaluation of several primary antibod-
ies (reviewed in the study by Weickhardt et al.24), including 
ALK1 (Dako), 5A4 (from different sources including Abcam 
and Novocastra, Newcastle Upon Tyne, United Kingdom), or 
D5F3 (Cell Signaling Technology, Danvers, MA),20 has been 
performed for IHC using FISH as a standard procedure com-
parator but occasionally in conjunction with RT-PCR.22 The 
difficulty in detecting the ALK antigenicity in NSCLC with 
ALK rearrangements led to the use of signal amplification 
systems such as tyramide amplification13 or other enhanced 
detection systems such as the ultraView system (Roche 
Ventana, Illkirch Graffenstaden, France)19,22 to maximize IHC 
sensitivity. Despite such improvements, a scoring system was 
also used in most series to evaluate staining intensity by eye. A 
2/3+ score seemed to be correlated with FISH-positive results, 
and IHC 1+ cases were mainly found to be FISH negative,19,23,27 
except in the series by Park et al.,28 in which five of six IHC 1+ 
cases were also FISH positive. This suggests that IHC inter-
pretation is not well standardized, as signal intensity depends 
on the IHC amplification procedure or preanalytical steps. 
Indeed, although most IHC cases displayed homogeneous 
staining, although at various intensities, we also recorded 
some focal-positive cases or cases with heterogeneous stain-
ing intensity as positive. Whether this represents tumor het-
erogeneity or fixation artifacts was not determined but may 
indicate that ALK immunoreactivity in NSCLC is peculiarly 
versatile and sensitive to preanalytical steps. Despite the use 
of a parallel positive control, the absence of an internal posi-
tive structure also makes it impossible to determine true non-
contributive specimens for IHC.
Several studies have supported the concept of screen-
ing patients with NSCLC by IHC and by using FISH only 
in positive cases or in patients with clinical and histologi-
cal features of ALK-positive NSCLC.19,27,29 Generally, the 
 above-mentioned parallel studies have not reported FISH 
positivity in IHC-negative cases except in the recent study by 
Wallander et al.22 However, in some studies, only  IHC-positive 
cases were screened by FISH, which would not allow the 
detection of FISH-positive/IHC-negative cases.30 In addition, 
true independence of FISH and IHC performance cannot be 
achieved when the same pathologists participate in both FISH 
and IHC interpretations and in studies with selected or non-
consecutive inclusions. Such information is generally lacking 
in most published studies aiming at a parallel evaluation of 
both techniques.13,20,22,31 Some individual ALK-positive cases 
with discordance between FISH and IHC were reported; how-
ever, this was explained either by absence of ALK protein 
detection because of a lack of staining protocol sensitivity20 or 
by failure in detecting ALK rearrangement with minimal sepa-
ration of the 3' and 5' ALK probes, as in the context of EML4/
ALK paracentric inversion.26 Finally, most comparative stud-
ies between IHC and FISH have been performed on a limited 
number of cases with artificial concordance generated by the 
high rate of double-negative cases of IHC and FISH.
During the last year, we have collected anonymous data 
from more than 3200 NSCLC patients with advanced or meta-
static diseases consecutively referred to our two university hos-
pital departments for the detection of both ALK rearrangements 
and ALK overexpression by FISH and IHC analyses, respec-
tively. No further selection was performed on these samples at 
the biological platform level. Interpretation of both techniques 
TABLE 3.  Comparative FISH/IHC Analysis in 3244 NSCLC 
Patients
FISH
Positive Negative NC Total
IHC Positive 80 19 15 114
Negative 36 2579 435 3050
NC 0 49 31 80
Total 116 2647 481 3244
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NC, 
noncontributive analysis or technical failure; NSCLC, non–small-cell lung cancer.
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was performed similarly in Rennes and Bordeaux, with IHC 
scored by trained pathologists (HB and DC). FISH was blindly 
analyzed by at least two cytogenetic readers who participated 
in the Polaris interlaboratory quality control program at the 
European level (in Bordeaux: JPM, AG, DD, LM, and GS; in 
Rennes: FC, MLC, MABR, and VJ). Note that the samples had 
been processed by many different pathology laboratories using 
various preanalytic protocols that may have impacted the find-
ings. Our study demonstrates an imbalanced sex ratio with a 
relative risk of 2.2-fold for female patients to harbor an ALK 
alteration. Such a sex ratio influence was previously reported by 
Zhou et al.32 but was not confirmed by other studies.14,27 ALK 
alteration was not shown to be restricted to adenocarcinoma 
but was present in the NOS NSCLC subtype. As previously 
found by other groups,32,33 ALK alteration was also detected 
in some SCC samples but only at a very low frequency. These 
data challenge the detection strategies in patients with advanced 
or metastatic NSCLC that suggest limiting ALK screening to 
adenocarcinoma,16 but the data are consistent with recent guide-
lines from the National Cancer Comprehensive Network that 
recommend analyzing all adenocarcinoma and NOS NSCLC 
cases and limiting analyses for SCC to never smokers and small 
biopsy specimens (version-2 2013 available from: www.nccn.
org). The rate of FISH  ALK-positive cases was 3.5%, which 
is consistent with previous data reported in white patients.19,33 
A similar rate of positive cases (3.6%) was also observed by 
IHC, thus demonstrating the absence of an overestimation by 
each method. The parallel studies conducted in Rennes and 
Bordeaux provided similar results and differed substantially 
from those claiming a global concordance between FISH and 
IHC for the detection of ALK abnormalities and supporting the 
use of IHC as a screening technique.19,34 Indeed, only 80 of the 
150 patients identified with an ALK alteration were detected 
by both FISH and IHC methods, whereas the remaining 70 
patients were detected by only one of the two techniques. Such 
a discrepancy was also mentioned in previous studies in which 
cases were positive by either IHC or FISH22,33,35,36 or in studies 
using RT-PCR, IHC, and FISH, demonstrating the complemen-
tarities of the different techniques.22
Our data support the fact that IHC may not detect all 
cases with ALK rearrangements, consistent with the recent 
report by Rodig et al.,13 who reported that approximately 
20% of FISH-positive cases remained IHC negative. The 
use of the D5F3 antibody (Cell Signaling Technology) in 17 
 FISH-positive/IHC-negative samples of the Bordeaux series 
in a second IHC testing allowed the detection of ALK expres-
sion in only five cases, whereas 12 cases remained negative, 
also underlining the versatility of ALK immunodetection in 
ALK-rearranged NSCLC (data not shown).
Several hypotheses could explain the absence or low 
level of ALK protein in FISH-positive cases. ALK protein 
expression in ALK-rearranged NSCLC was thought to be 
much lower than in ALK-rearranged anaplastic large-cell lym-
phoma.20 According to the fusion partner gene, the different 
chimeric ALK proteins were shown to have different hetero- 
or homo-dimerization properties and stabilities (for a review, 
see the study by Bergalet et al.37). The ALK rearrangement 
could also lead to a nontranslated ALK protein if the fusion 
gene is neither transcribed nor translated because of RNA 
decay or errors such as a stop codon in the open reading frame. 
As observed here,  FISH-positive  ALK-rearranged cases with 
negativity for ALK immunodetection have also been reported 
by several groups.22,33 In our study, many technical artifacts 
such as late fixation or overfixation may have impaired the 
appropriate detection of the ALK protein in FISH-positive 
cases, as we have included unselected consecutive samples 
originating from various pathology laboratories with hetero-
geneous fixation times of small biopsies and delays between 
removal and fixation of surgical lung samples by perfusion 
protocols.38 Other artifacts, including the possible mixture 
with acidic fixatives still used in France, may also have dif-
ferent consequences on the ability of FISH and IHC to detect 
ALK-positive cases, accounting for a portion of our discor-
dant cases. The variability in the preanalytical steps among 
pathology laboratories may partly explain why our two labora-
tories observed a high rate of discordant cases compared with 
single-institution studies.
However, several RT-PCR studies comparing IHC and 
FISH results have also reported different levels of ALK protein 
according to the type of EML4-ALK fusion gene. In particu-
lar, cases with EML4-ALK variant 1, as detected by RT-PCR, 
were hardly detectable by IHC with no or faint staining or by 
FISH, as the distance between the two ALK probes was less 
than two signal distances apart.22 It should be underlined that 
several experienced readers have reviewed the FISH slides of 
our discordant IHC and FISH cases, as the experience of the 
reader was found to be a critical parameter. However, it was 
not determined whether such cases contained EML4-ALK 
variant 1 transcripts. In the study by Wallander et al.,22 several 
 IHC-positive/FISH-negative cases were also reported to remain 
negative for EML4-ALK transcripts by RT-PCR amplification. 
In this study, fusion transcripts with other translocation part-
ners such as kinesin family member 5B, TRK-fused gene, and 
kinesin light chain 1 were not searched, but these rearrange-
ments would have been detected by BA FISH, as such translo-
cations lead to a wider physical separation of the 5' and 3' ALK 
probes than in the EML4-ALK inversion.39,40 Together with our 
19 IHC-positive/FISH-negative cases, the data by Wallander 
et al.22 also suggest the possibility of mechanisms other than 
ALK rearrangement leading to ALK expression in the discor-
dant FISH-negative NSCLC cases. Accordingly, ALK ampli-
fication or point-activating mutations have been shown to be 
associated with ALK expression and response to ALK inhibi-
tors in neuroblastoma, renal clear cell adenocarcinoma, or 
myofibroblastic tumors.41–43 In addition, among our discordant 
IHC-positive and FISH-negative cases, two cases were found 
to exhibit high levels of ALK polysomy with clusters of equal 
to or more than six fusion signals without BA or IRS signals. 
Such cases were classified among atypical FISH-negative 
cases using the criteria for EGFR amplification in NSCLC, 
and most of them were IHC negative for ALK.44,45 As a sub-
set of these atypical negative cases may be immunostained for 
ALK, such patients could be eligible for ALK inhibitors. The 
abundant focal amplification of ALK-native signals has been 
previously reported.24,26 Such a pattern was also observed in 
our concordant FISH-negative and IHC-negative cases but was 
however most frequently observed in scarce cells with large 
nuclei below a threshold of 15% of cells.
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In France, the Institut National du Cancer has founded 
a program for the prospective detection of emerging bio-
markers in cancer, particularly for ALK in NSCLC. To 
reduce costs, a hierarchical testing for ALK, BRAF, human 
epidermal growth factor receptor 2 (HER2), or  phosphati-
dylinositol-3-kinase catalytic subunit (PIK3CA) mutations 
in EGFR wild-type and KRAS wild-type samples has been 
discussed on the basis of studies reporting the absence of 
concomitant mutations in NSCLC cases.8–11 This criterion 
has also been included in an algorithm for screening ALK in 
clinically selected patients with NSCLC and an EGFR and 
KRAS  wild-type status.16 However, the absence of concomi-
tant mutations is questionable, as these mutations have been 
reported in other studies.32,46–48 In the present comprehensive 
study, we have not followed a hierarchical screening algo-
rithm and have identified eight cases with EGFR-activating 
mutations and 14 cases with KRAS mutations among our 
150 ALK-positive cases. Whether such ALK-positive cases 
with concomitant EGFR or KRAS mutations have a differ-
ent prognosis or response to ALK inhibitors remains to be 
determined. However, our data do not support a hierarchical 
algorithm based on molecular criteria.
Data on crizotinib response in patients who have been 
diagnosed differently by FISH and IHC are still preliminary. 
Thus, until large-scale studies in patients under therapy with 
crizotinib determine which testing is the most relevant to pre-
dict responses to ALK inhibition, our data support the need 
to routinely perform both analyses because of the difficulty in 
detecting the chimeric ALK protein in NSCLC and the pres-
ence of false-negative cases for each method. The limitations 
of each technique appear in our report of consecutive samples 
issued from various pathology laboratories, underlining the 
fact that the lack of standardization of preanalytical param-
eters may affect ALK protein detection by IHC and account 
for noncontributive cases of the FISH technique. These results 
also highlight that performing FISH analysis routinely for all 
NSCLC patients may require an automated process at various 
stages of the analysis (dewaxing, hybridization, screening of 
the hybridized slides with a camera to identify tumor cells, 
and signal scoring). Such a process is also mandatory because 
the biomarkers involved in the rearrangement or amplifica-
tion in NSCLC also include renal oncocytoma and sarcoma 
(ROS1) and rearranged during transfection (RET).49 In addi-
tion, we recently demonstrated that up to six sequential FISH 
hybridizations could be performed on a single section, dem-
onstrating that FISH is a practical tool for the study of sev-
eral chromosomal aberrations in samples of limited size and 
amount.50 Multiple FISH testing will likely be required until 
a robust  next-generation sequencing approach proves appli-
cable on a large scale in routine practice for chromosomal 
rearrangement detection.
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